Daly, Ann K.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†

Valenti, L., Al‐Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., Mozzi, E., Roviaro, G., Vanni, E., et al. (2010) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 651

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 623

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 549

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 499

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 479

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis

Selvaraj, E. A., Mózes, F. E., Jayaswal, A. N. A., Zafarmand, M. H., Vali, Y., Lee, J. A., Levick, C. K., Young, L. A. J., Palaniyappan, N., Liu, C.-H., et al. (2021) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 376

Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes

Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionPharmacogenetics and Drug Metabolism

Cited by 348

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis

Vali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 302

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 205

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023) · Nature Metabolism

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 178

Human leukocyte antigen B∗14:01 and B∗35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury

Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology

Drug-Induced Hepatotoxicity and ProtectionDrug-Induced Adverse Reactions

Cited by 76

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 28

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 23